CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 95 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2020. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,635,073 | +93.1% | 59,414 | +138.1% | 0.00% | – |
Q2 2023 | $846,791 | -65.3% | 24,957 | -63.2% | 0.00% | -100.0% |
Q1 2023 | $2,441,567 | +26.8% | 67,859 | +57.0% | 0.00% | 0.0% |
Q4 2022 | $1,925,825 | +105.5% | 43,209 | +29.7% | 0.00% | – |
Q3 2022 | $937,000 | -80.2% | 33,310 | -81.0% | 0.00% | -100.0% |
Q2 2022 | $4,731,000 | -26.7% | 175,506 | -7.4% | 0.00% | 0.0% |
Q1 2022 | $6,455,000 | +54.3% | 189,509 | +75.0% | 0.00% | +100.0% |
Q4 2021 | $4,184,000 | -4.1% | 108,300 | +34.0% | 0.00% | 0.0% |
Q3 2021 | $4,365,000 | +20.0% | 80,848 | -25.7% | 0.00% | 0.0% |
Q2 2021 | $3,639,000 | +111.2% | 108,836 | +30.1% | 0.00% | – |
Q1 2021 | $1,723,000 | +1.7% | 83,664 | -13.5% | 0.00% | – |
Q4 2020 | $1,695,000 | +159.2% | 96,732 | +119.3% | 0.00% | – |
Q3 2020 | $654,000 | -44.9% | 44,100 | -51.7% | 0.00% | – |
Q2 2020 | $1,187,000 | – | 91,276 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 2,600,000 | $88,218,000 | 12.13% |
Octagon Capital Advisors LP | 759,898 | $25,783,339 | 3.59% |
TSP Capital Management Group, LLC | 251,895 | $8,546,800 | 3.08% |
ACUTA CAPITAL PARTNERS, LLC | 122,343 | $4,151,098 | 2.81% |
5AM Venture Management, LLC | 310,270 | $10,527,461 | 2.62% |
COMMODORE CAPITAL LP | 631,665 | $21,432,393 | 2.41% |
RTW INVESTMENTS, LP | 3,463,201 | $117,506,410 | 2.24% |
Eversept Partners, LP | 785,740 | $26,660,158 | 2.23% |
Redmile Group, LLC | 1,696,004 | $57,545,416 | 2.21% |
Affinity Asset Advisors, LLC | 87,031 | $2,952,962 | 1.03% |